Literature DB >> 20299524

Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.

Inés González-Herrero1, Carolina Vicente-Dueñas, Alberto Orfao, Teresa Flores, Rafael Jiménez, César Cobaleda, Isidro Sánchez-García.   

Abstract

The existence of leukemia stem cells (LSCs) responsible for tumor maintenance has been firmly established. Therefore, therapeutic targeting of these LSCs may have a profound impact on cancer eradication. The anti-apoptotic protein Bcl2 has been proposed as a therapeutic target, but its role in LSC biology has not been investigated. In order to understand the role of Bcl2 in LSC generation and maintenance, we have taken advantage of our Sca1-BCRABLp210 mouse model of human chronic myeloid leukemia and bcl2 gene-targeted mice. This study provides genetic evidence that the inhibition of Bcl2 is not critical for the generation, selection or maintenance of the tumor initiating and maintaining cells in mice.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20299524      PMCID： PMC2893797          DOI： 10.1093/carcin/bgq062

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN： 0143-3334            Impact factor:   4.944


  27 in total

1.  Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.

Authors:  Daniel Primo; Juan Flores; Sandra Quijano; María Luz Sanchez; María Eugenia Sarasquete; Javier del Pino-Montes; Per Ivar Gaarder; Marcos Gonzalez; Alberto Orfao
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

2.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Authors:  Junya Kuroda; Hamsa Puthalakath; Mark S Cragg; Priscilla N Kelly; Philippe Bouillet; David C S Huang; Shinya Kimura; Oliver G Ottmann; Brian J Druker; Andreas Villunger; Andrew W Roberts; Andreas Strasser
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-22       Impact factor: 11.205

3.  Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.

Authors:  M Andreeff; S Jiang; X Zhang; M Konopleva; Z Estrov; V E Snell; Z Xie; M F Okcu; G Sanchez-Williams; J Dong; E H Estey; R C Champlin; S M Kornblau; J C Reed; S Zhao
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

4.  Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice.

Authors:  M Pérez-Caro; N Gutierrez-Cianca; I González-Herrero; I López-Hernández; T Flores; A Orfao; M Sánchez-Martín; A Gutiérrez-Adán; B Pintado; I Sánchez-García
Journal:  Oncogene       Date:  2006-09-18       Impact factor: 9.867

5.  Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.

Authors:  X Jiang; Y Zhao; C Smith; M Gasparetto; A Turhan; A Eaves; C Eaves
Journal:  Leukemia       Date:  2007-03-01       Impact factor: 11.528

6.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Authors:  Yiguo Hu; Sarah Swerdlow; Theodore M Duffy; Roberto Weinmann; Francis Y Lee; Shaoguang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-31       Impact factor: 11.205

7.  The stem of cancer.

Authors:  Riccardo Fodde
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

Review 8.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

9.  Targeting a chronic problem: elimination of cancer stem cells in CML.

Authors:  Claus Nerlov
Journal:  EMBO J       Date:  2009-02-04       Impact factor: 11.598

10.  Cancer induction by restriction of oncogene expression to the stem cell compartment.

Authors:  María Pérez-Caro; César Cobaleda; Inés González-Herrero; Carolina Vicente-Dueñas; Camino Bermejo-Rodríguez; Margarita Sánchez-Beato; Alberto Orfao; Belén Pintado; Teresa Flores; Manuel Sánchez-Martín; Rafael Jiménez; Miguel A Piris; Isidro Sánchez-García
Journal:  EMBO J       Date:  2008-11-27       Impact factor: 11.598
View more
  5 in total

1.  MALT lymphoma meets stem cells.

Authors:  Carolina Vicente-Dueñas; César Cobaleda; José Ángel Martínez-Climent; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2012-07-24       Impact factor: 4.534

2.  Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Authors:  J G Harb; P Neviani; B J Chyla; J J Ellis; G J Ferenchak; J J Oaks; C J Walker; P Hokland; D C Roy; M A Caligiuri; G Marcucci; C S Huettner; D Perrotti
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

3.  Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.

Authors:  Carolina Vicente-Dueñas; Marcos Barajas-Diego; Isabel Romero-Camarero; Inés González-Herrero; Teresa Flores; Isidro Sánchez-García
Journal:  Oncotarget       Date:  2012-03

4.  Genetic background affects susceptibility to tumoral stem cell reprogramming.

Authors:  Idoia García-Ramírez; Lucía Ruiz-Roca; Alberto Martín-Lorenzo; Oscar Blanco; María Begoña García-Cenador; Francisco Javier García-Criado; Carolina Vicente-Dueñas; Isidro Sánchez-García
Journal:  Cell Cycle       Date:  2013-07-08       Impact factor: 4.534

Review 5.  Telomerase and drug resistance in cancer.

Authors:  Natalia Lipinska; Aleksandra Romaniuk; Anna Paszel-Jaworska; Ewa Toton; Przemyslaw Kopczynski; Blazej Rubis
Journal:  Cell Mol Life Sci       Date:  2017-06-16       Impact factor: 9.261
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.